Novartis (US Pharmaceuticals)
(https://pharma.us.novartis.com) 📸 Data Snapshot: May 28, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
There is a complete absence of structured data or schema_json to verify the identity of the pharmaceutical business. No experts, team members, or founders are mentioned, leaving the site without a verifiable human or corporate footprint. The technical implementation is fundamentally broken, presenting a major credibility gap for a company expected to lead in precision medicine and biotechnology.
The site makes no performance claims in its current state, which in itself is a disconnect from the multi-billion-dollar brand equity of Novartis. By failing to demonstrate any pharmaceutical capability, the site provides zero proof of its implied role as a medical leader. The expected demonstration of capability is replaced by a system message regarding ‘Acquia Cloud customers,’ which is irrelevant to the pharma target audience.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
This page presents a snapshot of public data from Novartis (US Pharmaceuticals), captured on May 28, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Novartis (US Pharmaceuticals): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://pharma.us.novartis.com to view the most current version of its content and see directly what this company is about and what it offers.